


Hemoglobinopathy Treatment Drugs Market Size Is Anticipated To Reach US\$ 6.4 billion at a CAGR of 8.4% By 2028

Hemoglobinopathy includes a range of disorders, which occur due to altered structure of hemoglobin.

SEATTLE, WASHINGTON, UNITED STATES, February 7, 2022

/EINPresswire.com/ --

[Hemoglobinopathy Treatment Drugs Market](#) Report 2022-2028 includes a comprehensive analysis of the present Market. The report starts with the basic Hemoglobinopathy Treatment Drugs industry overview and then goes into each and every detail.



Hemoglobinopathy Treatment Drugs Market

Hemoglobinopathy Treatment Drugs Market Report contains in depth information major manufacturers, opportunities, challenges, and industry trends and their impact on the market forecast. Hemoglobinopathy Treatment Drugs also provides data about the company and its operations. This report also provides information on the Pricing Strategy, Brand Strategy, Target Client, Distributors/Traders List offered by the company.

Request Here For PDF Brochure With Latest Insights @

<https://www.coherentmarketinsights.com/insight/request-pdf/4059>

Hemoglobinopathy Treatment Drugs Market - Impact of Coronavirus (Covid-19) Pandemic

Blood disorders are one of the major causes of death worldwide. Therefore, demand for hemoglobinopathy treatment drugs were on rise during the COVID-19 pandemic. Thus, COVID-19 pandemic has not negatively impacted hemoglobinopathy treatment drugs market growth. However, the pandemic presents particular challenges and dangers to patients with hemoglobin disorders. Hemoglobin disorders are generally not associated with respiratory conditions. However, complications involving the heart, lungs, and the immune system, can be present in these patients and in a SARS-CoV-2 positive patient, it may trigger very serious complications.

Because of lockdowns in many countries across the globe, various patients with blood disorders at home are not able to receive prescribed medications.

The growing number of product approvals and launches, clinical trials of hemoglobinopathy treatment drugs, and partnerships among key players are the key factors driving growth of the hemoglobinopathy treatment drugs market during the forecast period.

The launch of new advanced hemoglobinopathy treatment drugs in the market is again projected to contribute to the hemoglobinopathy treatment drugs market growth. For instance, in November 2019, the U.S. Food and Drug Administration (FDA) approved crizanlizumab-tmca ADAKVEO, by Novartis to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. The recommended dose is 5 mg/kg intravenously over a period of 30 minutes on week 0, 2, and every 4 weeks thereafter. The most common adverse reactions (>10%) in patients receiving crizanlizumab-tmca were nausea, arthralgia, back pain, and pyrexia.

Get Sample Report With Latest Covid19 Analysis @

<https://www.coherentmarketinsights.com/insight/request-sample/4059>

Growing clinical trials for hemoglobinopathy treatment drugs is projected to augment growth of the hemoglobinopathy treatment drugs market over the forecast period. For instance, in March 2019, Cambridge, Massachusetts-based Imara Inc. announced that it raised US\$ 63 million Series B funding round, led by new investors OrbiMed and Arix Bioscience. The company raised the funds for the development of its lead product candidate, IMR-687, which is currently in a Phase II-a trial in sickle cell disease, and move it into later-stage clinical trials. IMR-687 is an inhibitor of phosphodiesterase-9, working on the same pathway as hydroxyurea, a generic chemotherapy drug commonly used to treat blood disorders and blood cancers.

Browse 31 Market Data Tables and 27 Figures spread through 158 Pages and in-depth TOC on Hemoglobinopathy Treatment Drugs Market, by Drug Type (Analgesics, Antibiotics, ACE Inhibitors, Hydroxyurea, and Others), by Disease Type (Thalassemia, Sickle Cell Disease, and Other Hb Variants Diseases), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Forecast to 2027"

Key market players are highly focused on adopting growth strategies such as partnership and collaboration for development of advanced hemoglobinopathy drugs in order to gain maximum share in the market. For instance, in May 2017, Sangamo Therapeutics, Inc. and Pfizer Inc. announced an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A, including SB-525, one of Sangamo's four lead product candidates. Under the terms of the collaboration agreement, Sangamo received a US\$ 70 million upfront payment from Pfizer. Sangamo conducted the SB-525 Phase 1/2 clinical study and certain manufacturing activities. Pfizer was responsible for

operationally and financially backing up Sangamo for subsequent research, development, manufacturing, and commercialization activities for SB-525 and additional products.

Key Takeaways of the Hemoglobinopathy Treatment Drugs Market:

The hemoglobinopathy treatment drugs market is expected to exhibit a CAGR of 8.4% during the forecast period (2020-2027), due to the growing number of product approvals and launches by key players

Among drug type, the hydroxyurea segment is expected to hold a major revenue share in 2027, due to growing demand for hydroxyurea medication to treat pediatric patients, which in turn would raise demand for hemoglobinopathy treatment drugs. For instance, in August 2018, Medunik USA Inc., a company working towards improving the health and quality of life of Americans with rare diseases by making orphan drugs available in the U.S., announced that U.S. FDA-approved orphan drug, Siklos (hydroxyurea) is now available in 100 mg tablets for pharmacies to order. Siklos is indicated to reduce the frequency of painful experiences and the need for blood transfusions in pediatric patients, two years of age and older, with sickle cell anemia with recurrent moderate to severe painful experiences.

key players engaged in the hemoglobinopathy treatment drugs market are Bristol-Myers Squibb Company, GlycoMimetics Inc., Pfizer Inc., Anthera Pharmaceuticals Inc., Eli Lilly and Company, Mast Therapeutics, Daiichi Sankyo Company Ltd., Novartis International AG, Bluebird Bio Inc., HemaQuest Pharmaceuticals Inc., Emmaus Medical Inc., Baxter International Inc., Merck & Co., Inc., Medunik USA Inc., Sangamo Therapeutics, Inc., Global Blood Therapeutics, Alnylam Pharmaceuticals, and Acceleron Pharma, Inc

Buy This Complete Business Report With Flat USD 2000 Off @
<https://www.coherentmarketinsights.com/promo/buynow/4059>

□□□ □□□□□□□□□ □□□ □□□ □□□□□ □□□□□□□□□□ □□□ □□□□ □□□□□□:

- SWOT Analysis focuses on worldwide main manufacturers to define, assess, and analyse market competition. By kind, application, and region, the market is defined, described, and forecasted.
- Examine the global and main regional market potential and advantage, opportunity and challenge, constraints and risks.
- Determine whether trends and factors are driving or limiting market growth.
- By identifying high-growth categories, stakeholders would be able to analyse market potential.
- Conduct a strategic study of each submarket's growth trends and market contribution.
- Expansions, agreements, new product launches, and acquisitions in the market are all examples of competitive developments.
- To create a strategic profile of the main players and analyse their growth plans in depth.

□□□□□ □□□□□□□

[Biliary Atresia Treatment Market](#)
[Yellow Fever Treatment Market](#)

□□□□□ □□:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Mr. Shah

Coherent Market Insights Pvt. Ltd.

+1 206-701-6702

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/562533788>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.